{"entity":{"id":"cd7","kind":"target","name":"CD7","aka":[],"tldr":"A T-cell surface marker kept on most T-cell leukaemias; CAR-T cells against it must be engineered not to kill each other, and they have produced remissions in T-ALL where nothing else worked.","summary":"CD7 is expressed on ~95% of T-ALL and T-lymphoblastic lymphoma, some NK/T lymphomas and ~30% of AML. CD7 CAR-T requires fratricide prevention (CD7 knockout, protein expression blockers or naturally selected CD7-negative T cells) and causes T-cell aplasia, so it is used as a bridge to allogeneic transplant. Trials in China (Peking University, Hebei Yanda) reported 90%+ complete remission in relapsed T-ALL (NEJM 2022, universal donor-derived CAR-T), and WU-CART-007 (allogeneic, US) received breakthrough status. Also a target for the ADC and for imaging in T-cell lymphoma.","asOf":"2026-09-08","wikipedia":"https://en.wikipedia.org/wiki/CD7","links":[{"label":"Donor-derived CD7 CAR-T (NEJM 2022)","url":"https://doi.org/10.1056/NEJMoa2117013"}],"tags":["gap-fill"],"related":[],"cancers":["all-leukemia","peripheral-t-cell-lymphoma","aml"],"sections":[],"technologies":["car-t","allogeneic-cell-therapy","allogeneic-hsct"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["nct05885464"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["The share of peripheral T-cell lymphomas retaining CD7 is not well characterised; CD7 is frequently lost in mature T-cell neoplasms and retained in a subset of NK/T lymphomas."],"symbol":"CD7","role":[],"sources":[],"specificitySources":[],"hgnc":"HGNC:1695","ensembl":"ENSG00000173762","uniprot":"P09564","entrez":"924","firstDescribed":1987,"firstDescribedBasis":"sequence","firstDescribedNote":"Earliest sequence paper UniProt cites for the protein: Aruffo et al, EMBO J, 1987, \"Molecular cloning of two CD7 (T-cell leukemia antigen) cDNAs by a COS cell expression system\".","firstDescribedSource":"https://pubmed.ncbi.nlm.nih.gov/3501369/","biology":"Ig-superfamily transmembrane glycoprotein on thymocytes, mature T and NK cells; ligand is SECTM1/K12; co-stimulatory role in early T-cell development.","whereFound":["T-ALL / T-LBL (~95%)","Extranodal NK/T-cell lymphoma, some PTCL","AML (~30%, shorter survival)"],"targetClass":"surface-antigen","prevalence":[{"cancerId":"all-leukemia","pct":">99","measure":"Flow cytometry, median % CD7+ blasts in 49 diagnostic T-ALL samples (incl. 14 ETP-ALL); stable at relapse and during chemotherapy","source":"https://doi.org/10.1182/bloodadvances.2017009928","note":"T-ALL/T-LBL only (~15% of ALL); B-ALL is CD7-negative"},{"cancerId":"aml","pct":30,"measure":"Flow cytometry, CD7 on leukaemic blasts (approximately 30% of AML patients)","source":"https://doi.org/10.1016/j.ymthe.2018.10.001","note":"CD7+ AML carries a worse prognosis"}]},"route":"/targets/cd7/","neighbours":{"cancer":[{"id":"all-leukemia","kind":"cancer","name":"Acute lymphoblastic leukaemia","route":"/cancers/all-leukemia/"},{"id":"aml","kind":"cancer","name":"Acute myeloid leukaemia","route":"/cancers/aml/"},{"id":"peripheral-t-cell-lymphoma","kind":"cancer","name":"Peripheral T-cell lymphomas (including cutaneous T-cell lymphoma)","route":"/cancers/peripheral-t-cell-lymphoma/"}],"technology":[{"id":"allogeneic-cell-therapy","kind":"technology","name":"Allogeneic (off-the-shelf) cell therapy","route":"/technologies/allogeneic-cell-therapy/"},{"id":"allogeneic-hsct","kind":"technology","name":"Allogeneic stem cell transplantation","route":"/technologies/allogeneic-hsct/"},{"id":"car-t","kind":"technology","name":"CAR-T cell therapy","route":"/technologies/car-t/"}],"trial":[{"id":"nct05885464","kind":"trial","name":"A Study Evaluating the Safety and Efficacy of BEAM-201 in Relapsed/Refractory T-Cell Acute Lymphoblastic Leukemia (T-ALL) or T-Cell Lymphoblastic Lymphoma (T-LL)","route":"/trials/nct05885464/"}]}}